Insmed Incorporated (INSM) Stock Analysis
Falling Knife setup
Healthcare · Biotechnology
Sell if holding. Momentum 1.9/10 is below the 5.0 floor at $107.47 — engine's falling-knife protection flags exit rather than catching a breakdown. Specifics: Concentration risk — Product: ARIKAYCE and BRINSUPRI; V7 low-quality RISK_OFF penalty: -0.5 (Q=4.9).
Insmed is a global biopharmaceutical company with two commercial products: ARIKAYCE (amikacin liposome inhalation suspension) approved for refractory MAC lung disease in the US, EU, and Japan, and BRINSUPRI (brensocatib) approved for non-cystic fibrosis bronchiectasis in the US... Read more
Sell if holding. Momentum 1.9/10 is below the 5.0 floor at $107.47 — engine's falling-knife protection flags exit rather than catching a breakdown. Specifics: Concentration risk — Product: ARIKAYCE and BRINSUPRI; V7 low-quality RISK_OFF penalty: -0.5 (Q=4.9). Chart setup: Death cross, below all MAs, RSI 32, MACD bearish. Score 5.1/10, moderate confidence.
Passes 7/8 gates (favorable risk/reward ratio, clean insider activity, no SEC red flags, news boost analyst 0.40, earnings proximity 78d clear, semi cycle peak clear, materials cycle peak clear). Fails on weak momentum. Suitability: moderate.
Recent Developments — Insmed Incorporated
Latest news
- Analysts’ Opinions Are Mixed on These Healthcare Stocks: United Therapeutics (UTHR), Insmed (INSM) and MannKind (MNKD) - — The Globe and Mail neutral
- Insmed and Ty Pennington Team Up to Drive Awareness and Proper Diagnosis of Bronchiectasis - PR Newswire — PR Newswire positive
- Insmed (INSM) CEO sells 10,699 shares and exercises options under 10b5-1 plan - Stock Titan — Stock Titan negative
- INSM (Insmed Incorporated) Q4 2025 EPS misses consensus estimates, shares rise 5.07 percent on positive investor sentime — Newser negative
- What Insmed Incorporated (INSM) does that keeps customers coming back (-0.41%) 2026-05-05 - Insider Selling - Newser — Newser negative
Generated 2026-05-20T21:06:21Z.
Thesis
Key Metrics
Quality Signals
Options Flow
Concentration Risks(10-K Item 1A)
- HIGHProductARIKAYCE and BRINSUPRI10-K Item 1A: 'Our prospects are highly dependent on the success of our approved products, ARIKAYCE and BRINSUPRI'
Material Events(8-K, last 90d)
- 2026-02-19Item 5.02LOWDavid W.J. McGirr, board member and Audit Committee chair, notified the board on February 17, 2026 that he will not stand for re-election at the 2026 Annual Meeting. Will serve until the meeting. Decision not a result of any disagreement.SEC filing →
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. Full disclaimer
Rating Breakdown
4 floor-breakers·1 ceiling hit
Price action weak — below key moving averages, no momentum carry. Needs a base before trend-continuation setups apply.static
Ranks in the bottom of its industry peers on the composite signal. Better names in the same sector exist.static
No near-term catalyst priced in. Thesis progression will come from fundamentals grinding, not event reaction.static
Priced at a premium — multiples above sector norms. Needs delivery on growth + margins to justify.static
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Sell if holding. Momentum 1.9/10 is below the 5.0 floor at $107.47 — engine's falling-knife protection flags exit rather than catching a breakdown. Specifics: Concentration risk — Product: ARIKAYCE and BRINSUPRI; V7 low-quality RISK_OFF penalty: -0.5 (Q=4.9). Chart setup: Death cross, below all MAs, RSI 32, MACD bearish. Prior stop was $99.89. Score 5.1/10, moderate confidence.
Take-profit target: $180.90 (+68.4% upside). Prior stop was $99.89. Stop-loss: $99.89.
Concentration risk — Product: ARIKAYCE and BRINSUPRI; V7 low-quality RISK_OFF penalty: -0.5 (Q=4.9); Leverage penalty (D/E 1.1): -0.5.
Insmed Incorporated trades at a P/E of N/A (forward 291.2). TrendMatrix value score: 3.9/10. Verdict: Sell.
28 analysts cover INSM with a consensus score of 4.3/5. Average price target: $201.
What does Insmed Incorporated do?Insmed is a global biopharmaceutical company with two commercial products: ARIKAYCE (amikacin liposome inhalation...
Insmed is a global biopharmaceutical company with two commercial products: ARIKAYCE (amikacin liposome inhalation suspension) approved for refractory MAC lung disease in the US, EU, and Japan, and BRINSUPRI (brensocatib) approved for non-cystic fibrosis bronchiectasis in the US (August 2025) and EU (November 2025). The pipeline includes TPIP (PH-ILD/PAH) in Phase 3 and gene therapy programs for DMD and ALS. The company has no history of profitability.